This is a phase 2, double-blind, randomized, placebo-controlled study to evaluate the activity of seladelpar in subjects with Non-alcoholic Steatohepatitis (NASH).
The primary objective is to evaluate the effect of seladelpar on hepatic fat fraction, assessed by MRI-PDFF at week 12 and to evaluate the safety and tolerability of seladelpar in subjects with NASH.
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.